Clinical Trials Directory

Trials / Completed

CompletedNCT07284862

A Cross-sectional Study on the Association of Peptidoglycan Fragments Derived From Gut Microbiota With Alcohol Liver Disease

Status
Completed
Phase
Study type
Observational
Enrollment
40 (actual)
Sponsor
Zhujiang Hospital · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Accepted

Summary

alcohol-associated liver disease (ALD) is a leading cause of cirrhosis, yet the role of gut microbiota-derived peptidoglycan (PG) metabolites in liver injury remains unclear. This study aimed to elucidate the role of microbial DL-endopeptidases, which generate NOD2 ligands, in modulating alcohol-induced liver injury.Participants will provide stool samples.

Conditions

Interventions

TypeNameDescription
OTHERAn observational, non-interventional study design.An observational, non-interventional study design.

Timeline

Start date
2025-07-01
Primary completion
2025-11-01
Completion
2025-11-01
First posted
2025-12-16
Last updated
2025-12-16

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT07284862. Inclusion in this directory is not an endorsement.